GB-1275

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameGB-1275
Drug Alias Nameleukadherinsintegrin CD11b/CD18 agonistsGB-1275ADH-503
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin beta-2 agonists
TargetsIntegrin beta-2
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsProstatic Neoplasms, Castration-Resistant +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGossamer Bio IncWashington University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive Companies149 Bio LLCGb006 Inc
Active IndicationsN/A
Inactive IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsProstatic Neoplasms, Castration-Resistant +[14] 

Other Information

ATC CodeN/A
Related LinksN/A